Titlebook: Deprenyl — Past and Future; W. Kuhn,P. Kraus,H. Przuntek Conference proceedings 1996 Springer-Verlag/Wien 1996 Alzheimer.Parkinson.diagnos

勾引

https://doi.org/10.1007/978-3-7091-7494-4Alzheimer; Parkinson; diagnosis; dopamine; psychiatric disorder

Rejuvenate

978-3-211-82891-5Springer-Verlag/Wien 1996

稀释前

Journal of Neural Transmission. Supplementahttp://image.papertrans.cn/d/image/265790.jpg

松果

Gratuitous

Habituate

moribund

,The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (−)-deprenyl reseaplex mechanism. The MAO-B inhibition could result in a potentiation of the effect and the reduction of the dose of L-dopa, including the restoration of the sensitivity to L-dopa treatment, when the response to the drug has already been diminished or lost. Pre-treatment with (−)deprenyl prevent the e

aneurysm

magnanimity

缩短

,Deprenyl in the treatment of Parkinson’s disease: clinical effects and speculations on mechanism ofputative neuroprotective therapy. Clinical trials demonstrate that selegiline slows the rate of disease progression and delays the appearance of disability necessitating levodopa. However, confounding symptomatic effects have made it difficult to ascertain the presence of any direct neuroprotective